Last reviewed · How we verify

NCT01041911

Double-blind, Randomized, Placebo-controlled, Dose Response Study to Evaluate the Safety and Efficacy of Three Doses of Euphorbia Prostrata Dry Extract Tablets in Patients of Hemorrhoids

Completed Phase 2 Last updated 4 December 2012
What this trial tests

Phase 2 trial testing Euphorbia tablets in Hemorrhoids in 102 participants. Completed in 1 November 2010.

Timeline
1 March 2010
Primary endpoint
1 October 2010
1 November 2010

Quick facts

Lead sponsorPanacea Biotec Ltd
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment102
Start date1 March 2010
Primary completion1 October 2010
Estimated completion1 November 2010
Sites6 locations across India

Drugs / interventions tested

Conditions studied

Sponsor

Panacea Biotec Ltd — full company profile →

Who can join

18 and older, any sex, with Hemorrhoids. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine the safe and efficacious dose of Euphorbia prostrata for control of per rectal bleeding in patients with first and second degree hemorrhoids.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. <i>Euphorbia</i>-Derived Natural Products with Potential for Use in Health Maintenance.
    Salehi B, Iriti M, Vitalini S, Antolak H, et al · · 2019 · cited 54× · PMID 31382529 · DOI 10.3390/biom9080337

Verify or expand the search:

Other recruiting trials for Hemorrhoids

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01041911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing